Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 248,000 ordinary shares on 22 October 2025 at a volume‑weighted average price of 1,644.38p (range: 1,625.00p–1,655.00p). The shares will be held as treasury shares and the transaction forms part of GSK’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,361,500 shares. Following this purchase, GSK holds 252,826,344 shares in treasury and has 4,062,590,575 shares in issue (excluding treasury), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.22%.
GSK reported positive pivotal phase III results for a next‑generation, low‑carbon version of its Ventolin (salbutamol) metered dose inhaler using propellant HFA‑152a. The data show therapeutic equivalence and a comparable safety profile to the current HFA‑134a formulation, supporting regulatory submissions with launch expected from 2026.
GSK notes approximately 300 million salbutamol MDIs are sold globally each year and that, if approved, the new inhaler has the potential to reduce greenhouse gas emissions by 92% per inhaler. The company added that its salbutamol MDI currently accounts for close to 45% of its total global carbon footprint.
GSK plc reported a share buyback transaction executed via BNP Paribas SA on 21 October 2025, purchasing 250,000 ordinary shares at prices between 1,635.00p and 1,650.00p, with a volume-weighted average price of 1,642.48p. The shares will be held as Treasury shares and the purchase forms part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 5,113,500 ordinary shares. Following this transaction, GSK holds 252,578,344 shares in treasury and has 4,062,838,575 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed that treasury-held ordinary shares represent 6.22% of voting rights.
GSK plc filed a Form 6-K announcing headline results from the INFRONT-3 trial of latozinemab in frontotemporal dementia due to progranulin mutation (FTD-GRN). The drug achieved a statistically significant effect on the biomarker co-primary endpoint, increasing plasma progranulin (PGRN), but did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data have not highlighted major concerns, and deeper analyses are ongoing.
Based on these results, GSK will discontinue the open-label extension portion of INFRONT-3 and the continuation study for latozinemab. Full results will be presented at an upcoming medical congress. GSK and Alector have collaborated on progranulin-elevating antibodies since July 2021, sharing development responsibilities and costs after Phase 2 proof-of-concept.
GSK reported that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of a new prefilled syringe presentation for Shingrix (Recombinant Zoster Vaccine). After approval by the European Commission, expected in December 2025, the ready-to-use format would eliminate reconstitution of two separate vials, simplifying administration for healthcare professionals.
Shingrix has been approved in the EU since 2018 for adults 50+ and since 2020 for adults 18+ at increased risk of herpes zoster. The positive opinion is based on data confirming technical comparability between the prefilled syringe and the current presentation. Shingles affects approximately 1.7 million people in Europe each year.
GSK plc repurchased 220,000 ordinary shares on 20 October 2025 as part of its existing buyback programme, executed via BNP Paribas SA. The shares will be held as treasury shares.
On the day, prices ranged from 1,615.00p to 1,637.00p, with a volume‑weighted average price of 1,628.13p. Since 30 September 2025, GSK has purchased 4,863,500 ordinary shares under this programme.
After this transaction, GSK holds 252,328,344 shares in treasury and has 4,063,088,575 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,088,575, and the percentage of voting rights attributable to treasury shares is 6.21%.
GSK plc reported positive pivotal Phase 3 PIVOT-PO results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs), including pyelonephritis. The trial was stopped early for efficacy and met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin based on overall response at the test-of-cure visit.
Oral tebipenem HBr (600 mg) achieved a 58.5% overall success rate (261/446) versus 60.2% for IV imipenem-cilastatin (500 mg; 291/483), with an adjusted treatment difference of −1.3% (95% CI: −7.5%, 4.8%). Clinical cure rates were 93.5% vs 95.2%, and microbiological responses were 60.3% vs 61.3%, respectively. The safety profile was generally similar to imipenem-cilastatin, with diarrhea and headache the most frequent, mild-to-moderate events.
GSK plans to work with US regulators to include these data in a filing in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem in the US for cUTIs, potentially providing a home-based treatment alternative.
GSK plc reported a routine share repurchase under its existing buyback programme. On 17 October 2025, the company bought 414,000 ordinary shares at prices between 1,597.50p and 1,620.50p, with a volume‑weighted average price of 1,608.93p. The shares will be held as treasury shares and the trades were executed by BNP Paribas SA.
Since 30 September 2025, GSK has purchased 4,643,500 ordinary shares. After this transaction, GSK holds 252,108,344 shares in treasury and has 4,063,308,575 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,063,308,575, and the percentage of voting rights attributable to treasury shares is 6.20%.
GSK plc reported a routine share buyback. Acting through BNP Paribas SA, the company purchased 310,000 ordinary shares on 16 October 2025 at prices between 1,621.50p and 1,637.00p per share, with a volume-weighted average price of 1,629.84p. The shares will be held as Treasury shares under the existing non-discretionary buyback agreement announced on 30 September 2025. Since that date, GSK has purchased 4,229,500 shares.
Following this transaction, GSK holds 251,694,344 shares in treasury and has 4,063,719,485 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,063,719,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc reported insider acquisitions of American Depositary Shares through automatic dividend reinvestment. On October 14, 2025, ADSs were acquired at $43.9461 per ADS on the New York Stock Exchange, reflecting the reinvestment of dividends paid on October 9, 2025.
Hal Barron acquired 3,186.736 ADSs. James Ford acquired 321.543 ADSs. Shobie Ramakrishnan acquired 387.334 ADSs. Each entry is recorded as a single transaction, with the instrument identified as GSK ADSs (ISIN: US37733W2044).
These transactions are routine dividend reinvestments by directors and senior management and do not reflect an open‑market discretionary purchase program.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
